Surmodics, Inc.: 6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Sundance Sirolimus DCB demonstrates lowest binary restenosis at 6 months compared to relevant BTK clinical trials Excellent safety profile observed with no major amputations and low rates of MAE Surmodics

Related Keywords

Minnesota ,United States ,Australia ,Lugano ,Ticino ,Switzerland ,Eden Prairie ,New Zealand ,Ramon Varcoe ,Andrew Holden ,Sundance Sirolimus ,Tim Arens ,Surmodics Inc ,Nasdaq ,Amputation Prevention Symposium ,Late Lumen Loss ,Professor Ramon Varcoe ,Swing Trial ,Professor Andrew Holden ,Sundance Sirolimus Drug Coated ,Sundance Sirolimus Drug Coated Balloon ,Annual Report ,Surmodics ,Month ,Data ,Rom ,Wing ,First ,Human ,Trial ,Resented ,Europe ,